摘要
随着对IBD的临床表现及其发病机制认识的深入、药物开发的进展、对IBD药物治疗临床证据的积累,IBD药物治疗所使用的品种、方案和策略逐渐演进。遵循循证医学证据的临床指南的推荐意见仍然推荐"上阶梯"的药物治疗策略。
出处
《临床药物治疗杂志》
2011年第2期13-16,共4页
Clinical Medication Journal
参考文献11
-
1Allchin WH. Uleuative Colilis. An address introduetory, to the subject[J]. Proc Roy Soc Med,1909,2 :59- 75.
-
2Kirner JB. Historieal aspects of inflammatory bowel disease[ J ]. J Clin Gastroenterol. 1988,10:286-97.
-
3Svartz N. Sulfasalazine, 11. Some notes on the discovery, and devel- opment of salazopyrin[J]. Am J Gastroenterol,1988 ,83 :497- 503.
-
4Svartz N. Salaropyrin - a nev, sulfanilamide preparation. A. Therapeutic resuh in rheumatoid arlhritis. B. Therapeutie resuhs in ul-eerative colitis. C. Toxic manifestations on lreatment with sulfanila- midc preparations[J]. Aeta Mcd Stand, 1942,110:577-590.
-
5Azad - Khan AK, Pirls J, Truelove SC. An experiment to deter- mine the active therapeutic moiety of sulphasalazine, [J]. Lancet, 1977,2:892- 895.
-
6Truelove SC, Witts LJ. Cortisone in uleerative colitis. Report on therapeutic trial[J]. Br Med.J,1955,2:1041-8.
-
7Bean RHD. The treatment of chronic ulcerative colitis with 6 - mercaptopurine[J]. Med J Aust,1962,1:592- 593.
-
8Bowen GE, Irons GV, Rhodes JB, et al. Early experiences with azathioprine in ulcerative colitis; a note of caution [J]. JAMA, 1966, 195:460- 464.
-
9Targan SR, Hanauer SB, van Deventer S J, et al. A short - term study of chimeric monoclonal antibody cA2 to tumor necrosis factoralpha for Crohn's disease. Crohn's Disease cA2 Study Group[ J]. N Engl J Med,1997, 337:1029- 1035.
-
10Bernstein CN, Fried M, Krabshuis JH,et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in2010[J]. Inflamm Bowel Dis, 2010,16:112-124.
二级参考文献21
-
1Bernstein CN,Fried M,Krabshuis JH,et al.World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.Inflamm Bowel Dis,2010,16:112-124.
-
2Truelove SC,Witts U.Cortisone in ulcerative colitis; final report on therapeutic trial.Br Med J,1955,2:1041-1048.
-
3Sutherland LR,Martin F,Greer S,et al.5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis,proctosigmoi-ditis,and proctitis.Gastroenterology,1987,92:1894-1898.
-
4Elliott PR,Lennard-Jones JE,Hathway N.Simple index of Crohn's disease activity.Lancet,1980,1:876.
-
5Carter MJ,Lobo AJ,Travis SP.Guidelines for the management of inflammatory bowel disease in adults.Gut,2004,53:V1-V16.
-
6Lichtenstein GR,Abreu MT,Cohen R,et al.American Gastroenterological Association Institute medical position statement on corticosteroids,immunomodulators,and infliximab in inflammatory bowel disease.Gastroenterology,2006,130:935-939.
-
7Lichtenstein GR,Abreu MT,Cohen R,et al.American Gastroenterological Association Institute technical review on corticosteroids,immunomodulators,and infliximab in inflammatory bowel disease.Gastroenterology,2006,130:940-987.
-
8Hanauer SB,Sandborn WJ,Rutgeerts P,et al.Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease:the CLASSIC-I trial.Gastroenterology,2006,130:323-333.
-
9Schreiber S,Rutgeerts P,Fedorak RN,et al.A randomized,placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.Gastroenterology,2005,129:807-818.
-
10Jarnerot G,Hertervig E,Friis-Liby I,et al.Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:a randomized,placebo-controlled study.Gastroenterology,2005,128:1805-1811.
共引文献45
-
1许春娣,王歆琼.关注儿童炎症性肠病的诊断策略[J].中华儿科杂志,2011,49(4):241-244. 被引量:3
-
2潘庚,朱桢.康复新液保留灌肠治疗溃疡性结肠炎[J].临床荟萃,2011,26(14):1258-1259. 被引量:9
-
3潘庚.改良康复新液保留灌肠治疗溃疡性结肠炎的疗效及对复发率的影响[J].中国老年学杂志,2012,32(11):2401-2402. 被引量:22
-
4潘庚,朱桢.改良康复新液保留灌肠治疗溃疡性结肠炎疗效及对血清凝血指标的影响[J].河北医药,2012,34(11):1623-1625. 被引量:17
-
5温凌,黄建伟,王巧瑜,张美华,潘洁.炎症性肠病患者胸腺近期输出功能变化[J].广州医学院学报,2012,40(6):56-59.
-
6张月萍,王连祥.康复新联合美沙拉嗪治疗溃疡性结肠炎58例临床分析[J].山西医药杂志(下半月),2013,42(6):664-665. 被引量:1
-
7黄夺夏,陆翠钦,何张平.美沙拉嗪与康复新液联合治疗老年溃疡性结肠炎的疗效及对血清炎症细胞因子、凝血指标的影响[J].中国老年学杂志,2013,33(15):3769-3770. 被引量:70
-
8阎爱华,龙海华,梁秀兰,陈春妮.中西医结合治疗溃疡性结肠炎疗效分析[J].海南医学,2013,24(19):2832-2834. 被引量:3
-
9王佳林.乌梅丸治疗溃疡性结肠炎的疗效观察及对血清IL-4和IL-8水平的影响[J].海南医学院学报,2014,20(1):80-82. 被引量:20
-
10何飞龙,金玉弟,袁金仁,张永力,柳峰.康复新液、云南白药联合柳氮磺吡啶保留灌肠治疗溃疡性结肠炎[J].长春中医药大学学报,2014,30(1):114-116. 被引量:11
同被引文献1624
-
1简序,王金和,程佩兰.C反应蛋白的临床研究进展[J].国际检验医学杂志,2004,26(5):471-473. 被引量:137
-
2高君荣,孙现广,韩世良.急性腹痛疾病的临床分析[J].中国现代应用药学,2007,24(z1):672-673. 被引量:18
-
3曹文广,苏宝珠,王录全,韩迎春.螺旋CT在孤立性肺结节中的诊断优势[J].实用医技杂志,2008,15(4):434-436. 被引量:4
-
4林晓生,谢昌辉,段清萍.^(99m)Tc-MAA显像、X线片、超声、CT和肺动脉造影诊断肺栓塞的比较研究[J].中国实用医药,2006,1(9):19-21. 被引量:2
-
5李萍,胡建华.高频超声诊断毛囊皮脂腺囊肿的临床价值[J].中国超声诊断杂志,2006,7(8):609-611. 被引量:2
-
6杨沛钦,郑晓林,郭友,何惜金,吕明德,徐辉雄.MRI多种成像技术在小肝癌诊断中的价值[J].中国CT和MRI杂志,2006,4(3):21-24. 被引量:15
-
7何东仪,钟丽民,沈杰,程鹏,李卓伶,姜婷.葡萄糖6-磷酸异构酶检测在类风湿关节炎中的意义[J].现代免疫学,2008,28(4):326-330. 被引量:8
-
8张天弼,廖建军.多发性骨髓瘤误诊65例分析[J].中国误诊学杂志,2005,5(17):3329-3330. 被引量:8
-
9万里凯,张琴,许春梅,杨苏萍,王小燕.18~35岁中心性肥胖者颈动脉的超声研究[J].广西医学院学报,2008,18(3):392-394. 被引量:5
-
10邱创嘉,郭炜,潘寿岩,吴映南,郑粤军,陈卫镇.鼻骨骨折螺旋CT3D成像与X线片对比研究[J].中国法医学杂志,2004,19(S1):11-12. 被引量:9
二级引证文献6
-
1耿秀文.炎性肠病的临床手术治疗方法及疗效评价[J].中国医药指南,2014,12(33):182-183. 被引量:1
-
2费燕,朱金平,黄志红.3例克罗恩病个体化营养支持方案分析[J].医药导报,2015,34(11):1537-1539. 被引量:1
-
3王晖,黄海涛,梁三红,吕文.英夫利西单抗联合硫唑嘌呤片对炎症性肠病患者T淋巴细胞的影响[J].实用药物与临床,2017,20(9):1039-1042. 被引量:12
-
4赵红莉,杨海侠,杨会,王双妮,汪永华,符翠,范清.医护患微信群互动对炎性肠病患者自我健康管理能力的研究[J].检验医学与临床,2018,15(4):527-529. 被引量:5
-
5陈佩玲,谢伦芳.克罗恩病患者应用英夫利西单抗的输液不良反应[J].医药导报,2020,39(12):1756-1759. 被引量:2
-
6周宜,刘晓琴,吴学敏,张浩,王海琴,王红亮,孟祥龙.乳香及其炮制品对葡聚糖硫酸钠诱导小鼠炎症性肠病的保护作用[J].现代药物与临床,2022,37(7):1432-1438. 被引量:4
-
1张蓉,李广平,郭乐凌.高血压治疗策略的转变[J].医学综述,2005,11(3):225-227. 被引量:3
-
2褚熙,王艳清.急性冠脉综合征的药物治疗策略[J].山东医药,2010,50(5):101-103. 被引量:1
-
3梁艺.不稳定心绞痛的药物治疗策略研究[J].临床医学工程,2009,16(3):105-105. 被引量:3
-
4王继光.动态血压监测与药物治疗策略[J].中华医学信息导报,2015,0(21):13-13.
-
5Wal RMA,Voors AA,Plokker HWM,张纪良(节译),曾朝荣(校).慢性心力衰竭新的药物治疗策略[J].心血管病学进展,2006,27(2):233-235. 被引量:4
-
6陶可胜,李建.胃食管反流病药物治疗方案和策略[J].中国社区医师,2010,26(8):11-11. 被引量:1
-
7高良熙,周西颜,高希斋.类风湿关节炎的药物治疗策略[J].临沂医学专科学校学报,2001,23(4):265-266.
-
8赵梦华,石建平,田洪森.心房颤动的药物治疗策略[J].临床急诊杂志,2003,4(3):40-42. 被引量:7
-
9蔡瑜,沈锡中.炎性肠疾病的药物治疗策略[J].世界临床药物,2005,26(7):405-409.
-
10王少峰,周春华.胃食管反流病的药物治疗策略[J].临床药物治疗杂志,2009,7(4):18-21. 被引量:5